Biothera, Cypress Settle Lawsuit

Biothera, Cypress Settle Lawsuit

EAGAN, Minn. & FRESNO, Calif.CypressSystems and Biothera Inc. reached a settlement in a patent infringement suitfiled by Biothera in early 2005 in Minnesota federal district court. Under termsof the settlement, Cypress will stop selling beta-glucan, will assign its BetaPrecise trademark to Biothera, and acknowledge the validity of Biotheraspatents covering beta-glucan dietary supplements. Biothera holds more than 40U.S. patents and patents pending covering the right to manufacture and sellyeast beta-glucan as a dietary supplement.

Richard Mueller, president and chief executive officer (CEO)of Biothera (www.biotherapharma.com), said, [The settlement] adds clarity tothe market for beta-glucan products, provides Biothera with new sales andfurther strengthens our position in two pending patent infringement lawsuits.Those lawsuits, against Biotec Pharmacon ASA and Fenchem Enterprises Ltd., werefiled in March 2005 and are still pending.

For more information on Cypress Systems, visitwww.cypsystems.com or Booth #8072 at SupplySide West.